Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Agrawal, B.
Right arrow Articles by Gretz, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Agrawal, B.
Right arrow Articles by Gretz, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrology Dialysis Transplantation, Vol 13, Issue 2 331-337, Copyright © 1998 by Oxford University Press

ORIGINAL ARTICLES

Acute effects of bezafibrate on blood pressure and renal haemodynamics in SHR and WKY rats

B Agrawal, J Kopecky, B Kranzlin, P Rohmeiss, J Pill and N Gretz
Medical Research Center, Klinikum Mannheim, University of Heidelberg, D-68167 Mannheim, FRG; Institute of Experimental Biopharmaceutics, Academy of Sciences of the Czech Republic, Hradec Kralove, Czech Republic; V. Medical Department, Klinikum Mannheim, University of Heidelberg, Heidelberg, FRG; Boehringer Mannheim, Mannheim, FRG; Corresponding author

Background. Bezafibrate, a fabric acid analogue, has well-established lipid- and fibrinogen-lowering properties. Some data exist pointing towards a blood pressure-lowering effect of bezafibrate. Thus the aim of this study was to examine the acute effect of bezafibrate on blood pressure and renal haemodynamics in hypertensive and normotensive rats. Methods. 8 Wistar-Kyoto (WKY) and 12 spontaneously hypertensive rats (SHR) were treated with i.v. bolus injections of vehicle and 1-10mg of bezafibrate in increasing doses every 15min. Mean arterial pressure (MAP), renal blood flow (RBF) were monitored continuously, together with plasma renin activity (PRA), urine volume and urinary Na+, K+, and protein concentration (15-min intervals).Results. Bezafibrate reduced MAP in, a dose-dependent manner (mean±SEM): in WKY, 1 mg bezafibrate, -1.13±0.61 mmHg and after 10 mg bezafibrate, -7.25±1.10 mmHg; in SHR, -0.60±0.43 and -5.83±0.90 mmHg respectively. In contrast to vehicle, bezafibrate induced a dose-dependent increase in RBF (WKY, 0.21±0.10 and 0.83±0.48 ml/min; SHR, 0.38±0.10 and 3.09±0.45 ml/min respectively) and a corresponding decrease in renal vascular resistance which was significantly greater in SHR than in WKY. The increase in RBF was paralleled by an increase in CBF. No effect of bezafibrate on MBF, PRA, urine flow, or urinary Na+, K+ or protein excretion was observed. The observed effects could not be attributed to one of the classic vasodilating mechanisms. Conclusions. We conclude that in rats bezafibrate is a potent hypotensive drug exhibiting additional effects on renal haemodynamics. Keywords: bezafibrate; blood pressure; cortical blood flow; renal haemodynamics; medullary blood flow; renal blood flow; SHR; WKY rats
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.